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ABSTRACT
Purpose Determine the pharmacokinetics of insulin peglispro
(BIL) in 5/6-nephrectomized rats and study the absorption in
lymph duct cannulated (LDC) sheep.
Methods BIL is insulin lispro modified with 20-kDa linear
PEG at lysine B28 increasing the hydrodynamic size to 4-
fold larger than insulin lispro. Pharmacokinetics of BIL and
insulin lispro after IV administration were compared in 5/6-
nephrectomized and sham rats. BIL was administered IV or
SC into the interdigital space of the hind leg, and peripheral
lymph and/or serum samples were collected from both LDC
and non-LDC sheep to determine pharmacokinetics and ab-
sorption route of BIL.
Results The clearance of BIL was similar in 5/6-
nephrectomized and sham rats, while the clearance of insulin
lispro was 3.3-fold slower in 5/6-nephrectomized rats than in
the sham rats. In non-LDC sheep, the terminal half-life after
SC was about twice as long vs IV suggesting flip-flop pharma-
cokinetics. In LDC sheep, bioavailability decreased to <2%;
most of the dose was absorbed via the lymphatic system, with
88% ± 19% of the dose collected in the lymph after SC
administration.
Conclusion This work demonstrates that increasing the hy-
drodynamic size of insulin lispro through PEGylation can im-
pact both absorption and clearance to prolong drug action.
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ABBREVIATIONS
AUC0-t Area under the serum concentration-time
curve from 0 to time of the last sample with a
quantifiable concentration
BIL Basal insulin peglispro
Co Serum concentration extrapolated to time 0
after IV administration
CL Total body clearance from serum
Cmax Maximum observed serum concentration
D Diffusion constant
DLS Dynamic light scattering
DH Apparent hydrodynamic diameter
ELISA Enzyme-linked immunosorbant assay
LDC Lymph duct cannulated
MW Molecular weight
OD276 Optical density at 276 nm
Pa Pascal






Rh Apparent hydrodynamic radius
RIA Radio-immunoassay
rpm Revolution per minute
SC Subcutaneous
SD Standard deviation
T1/2 Terminal elimination half-life
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T Absolute temperature
Tmax Time at the maximum concentration in serum
Vdss Volume of distribution at steady state
INTRODUCTION
Adequate and stable basal insulin levels are a critical compo-
nent of diabetes therapy because they regulate hepatic glucose
output, which is essential for proper maintenance of glucose
homeostasis during the diurnal cycle and inter-meal periods
and they help to minimize nocturnal hypoglycemia (1). Over
the past ~75 years, various strategies have been employed to
provide basal insulin therapy for patients with diabetes.
Initially, insulin suspension formulations (e.g., Ultralente,
Lente, and NPH) were used to delay the release of insulin
from the subcutaneous (SC) site of injection (2–4). However,
these early basal formulations poorly mimicked the flat phys-
iologic profile of basal insulin, and in the case of NPH, had a
short duration of action (<24 h) (5). The introduction of insu-
lin analogs and derivatives (e.g., insulin glargine, insulin
detemir) coupled with an appropriate formulation strategy
has shifted insulin therapy from suspension-based products
to solution-based products. Moreover with insulin detemir,(6)
this solution-based product reduced the variability observed in
the suspension-based products (7–9). However, these ap-
proaches fall short of being true once-daily basal insulin sub-
stitutes in all patients (10,11); thus, there remains a need for a
new generation of basal insulin products with sufficient dura-
tion of action to suffice as true once-daily basal insulin
therapy.
Current basal insulin treatments attempt to prolong the
residence time of insulin in the body and thus, prolong the
duration of action. Decreasing clearance is a potential way to
prolong the residence time of insulin in the body. Because the
kidney plays a role in the elimination of insulin, one strategy
for prolonging the duration of action of insulin could be de-
creasing renal clearance by decreasing the glomerular filtra-
tion and/or catabolism of insulin that occurs in the kidneys. A
5/6-nephectomized rat model can be used to study the impact
of renal clearance on the overall clearance of a molecule. In
this model, the kidney function of the rat is decreased by
approximately 83%, which would be sufficient to affect the
systemic clearance of a molecule that is prone to renal clear-
ance, such as insulin.
In addition to slowing clearance, another potential mech-
anism to increase the duration of action is to prolong absorp-
tion from the SC injection. After SC administration, a protein
therapeutic at the injection site can be absorbed via the blood
capillary system and/or the peripheral lymph system (12).
When a therapeutic protein dose is absorbed via the blood
capillary system, it is immediately present in the systemic cir-
culation compared with absorption into peripheral lymph
where the protein is transported through the central lymphatic
system and then drains into the systemic blood circulation via
the right and left subclavian veins (13,14). The route of protein
absorption after SC administration has been correlated to
molecular weight of the protein (14–16) and a function of
the endothe l ia l basement membrane s t ruc ture .
Microvascular beds are primarily composed of continuous
endothelial cell-cell interfaces characterized by tight adherens
junctions that are impermeant to molecules the size of albu-
min (MW= 69 kDa), but, allow permeability for lower mo-
lecular weight molecules (17,18). Lymphatic capillaries have
an incomplete basement membrane made from a single layer
of overlapping endothelial cells and no tight junctions, leaving
the vessel permeable to larger molecular weight macromole-
cules (14,19). Alternatively, in the case of insulin degludec,
protein absorption has been delayed by the formation of
multi-hexamers in the subcutaneous depot from di-hexamers
in the pharmaceutical formulation upon diffusion of phenol
from the formulation following injection (6).
Although SC drug administration is widely used, the bio-
availability of drugs administered via this route remains highly
variable, with few studies measuring the extent of uptake into
the lymphatic system (20). Other factors that may affect the
rate of absorption of a SC injection beyond the molecular
weight of the molecule are the charge on the molecule surface
and the formulation; as these factors affect the movement of
the molecule in the extracellular matrix.
A lymph duct-cannulated (LDC) sheep model has been
used in several studies to measure lymphatic absorption.
This model provides an understanding of lymphatic absorp-
tion and bioavailability of drugs as a function of molecular
weight (21–24). The LDC sheep model allows for simulta-
neous collection of peripheral lymph and sampling of blood
over an extended time. The samples from the LDC sheep are
compared with intact, non-LDC sheep to elucidate the rela-
tionship between lymphatic transport and drug bioavailability
(20).
The LDC sheep model has been used to identify the route
of absorption of SC-administered, commercially formulated
human insulin. Charman and colleagues tested the hypothesis
that hexameric-formulated human insulin is absorbed by the
capillary system and to a lesser degree by the lymphatic
system.(13) In LDC sheep, 17.3% of the insulin dose was re-
covered in the peripheral lymph demonstrating that lymph
absorption was a contributor to the overall insulin bioavail-
ability (13). Over multiple studies, Porter and colleagues have
demonstrated that molecular weight (MW) correlates with the
proportion of the dose absorbed (14–16).
The objective of these studies was to determine what im-
pact hydrodynamic size of basal insulin peglispro may have on
the absorption and clearance of insulin. This report charac-
terizes the impact of the addition of a 20-kDa PEG to insulin
lispro, the route of absorption in a lymph duct-cannulated
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The PEGylation, purification, quantification, and formula-
tion and stability of BIL used in animal studies are well defined
in the US patent for BIL (25). The PEG reagent was pur-
chased from the NOF Corporation (Tokyo, Japan). Eli Lilly
and Company provided the BIL used in the studies. In sum-
mary, preparation of BIL was achieved using basic pH condi-
tions at 4°C. Concentrated activated-PEG (para-nitro-
phenylcarbonate activated methoxy-PEG) solutions were pre-
pared in water at 4°C. Reactions were initiated by titration of
the PEG solutions into the insulin lispro using a syringe pump
(New Era Pump Systems, Inc., Model NE-300, Serial 232508
[Farmingdale, NY]) at a rate of addition varying from 0.5 to
3.5 mL/min. The reaction solution pH was maintained at
~11.0 by addition of base (NaOH or tribasic sodium phos-
phate). The reaction temperature was maintained at 4°C. At
the completion of the reaction (0.5–4 h), the temperature was
increased to 25°C and held for an additional 3.5 h. Reaction
progress was monitored using a C8-based reversed-phase high
performance liquid chromatography (RP-HPLC) method.
The PEGylation reaction was stopped by adjusting the pH
to 4.4 to 5. BIL was purified using either preparative C8-
based RP-HPLC for small-scale preparations or cation ex-
change chromatography for large-scale preparations. The
mono-PEGylated insulin lispro was eluted using either an
acetonitrile-based gradient (RP-HPLC) or a NaCl-based
step-gradient (cation exchange).
For the sheep studies normal saline and water for injection
were sourced from Baxter Healthcare (Old Toongabbie,
Queensland, Australia) and sodium heparin (1000 IU/mL)
from Hospira (Mulgrave, Victoria, Australia). Sodium ethyl-
enediaminetetraacetic acid (EDTA), TRIS base, sodium chlo-
ride, zinc oxide and m-cresol were purchased from Sigma-
Aldrich (MA, USA). All other reagents used were of AR
quality.
Hydrodynamic Size Determinations
The hydrodynamic size of BIL, leptin, and insulin was deter-
mined using dynamic light scattering (DLS) measurements.
Solutions were prepared from either freeze-dried powders or
concentrated protein stock solutions (or both) of insulin lispro
or PEGylated insulin lispro. Weighed-samples of freeze-dried
powder were dissolved in 1x phosphate-buffered saline (PBS)
to a final concentration of ~85 μM. Concentrated protein
stock solutions were diluted ~20-fold in 1 × PBS buffer to
achieve a final concentration of ~85 μM. Protein concentra-
tions (OD276 (1 mg/ml) = 1 for a 1 cm cuvette) were measured
by NanoDrop (Thermo Fisher Scientific, Waltham, MA,
USA). All samples were filtered through Whatman
Anatop10™ low protein-binding filters (Whatman, Kent,
UK) before the DLS experiments. Solution viscosity was mea-
sured by an m-VROC® (RheoSense, Inc., San Ramon, CA,
USA) viscometer and light scattering data were corrected
using the measured viscosity.
DLS measurements were carried out at 25 ± 1°C at a 90°
scattering angle using an ALV/CGS-3 Compact Goniometer
system with ALV/LSE-5003 Light Scattering Electronics and
Multiple Tau Digital Correlator (ALV®-GmbH, Langen,
Germany). The laser operating wavelength was 633 nm.
The apparent hydrodynamic radius Rh was estimated via
the Stoke-Einstein equation (Eq. 1):
Rh ¼ kBT6πηD ð1Þ
where, Rh is the apparent hydrodynamic radius (m), kB is the
Boltzmann constant (kg●m2/s2●K), T is the absolute temper-
ature (K), η is the viscosity (kg/m•s), and D is the diffusion
constant (m2/s). DH is the apparent hydrodynamic diameter
in nm or 2 Rh in nm. The viscosity measurement was per-
formed with a solution concentration of 0.49 ± 0.02 mg/mL
at 25°C. Viscosity mean and SD was determined from n ≥8
and reported as cP, (g/cm•s) = 10−3 × Pa•s (kg/m•s)
Animals
Rodents were maintained in accordance with the Institutional
Animals Care and Use Committee of Eli Lilly and Company
and the National Institute of Health Guide for the Use and
Care of Laboratory Animals. For the sheep models, all proce-
dures were approved by the Monash University animal ethics
committee and conducted in accordance to the Australian
Code of Practice for the Care and Use of Animals for
Scientific Purposes.
5/6-nephrectomized Rat Model
The 5/6-nephrectomized and sham male Sprague Dawley
rats were obtained from Taconic Farms (Albany, NY, USA).
Animals were housed two per cage in polycarbonate cages
with filter tops. Animals were maintained on a 12/12 h
light/dark cycle (lights on at 6:00 AM). All animals received
water and LabDiet 5001 (PMI Nutrition International,
Brentwood, MO, USA) ad libitum. Animals were monitored
daily during the 5-week time frame that allowed progression
of the disease state. Seven weeks post-surgery, blood was col-
lected by tail clip into serum tubes for measurement of serum
creatinine and blood urea nitrogen. Three days later, urine
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was collected for 24 h from animals housed in metabolism
cages. Animals were block-randomized into groups based on
body weight, 24-h urinary protein, and serum creatinine. On
the day of study, animals were separated into individual cages,
weighed, and bled by tail into a serum tube for the pooled
group exposure sample at time, T = 0. Animals were then
anesthetized with isoflurane and administered insulin lispro
or BIL at 10 nmol/kg by penile vein injection at a dose volume
of 1 mL/kg. Blood was collected via retro-orbital and/or tail
bleeding at multiple time points after injection. At the last time
point after injection, animals underwent CO2 inhalation, car-
diac puncture to collect blood, and cervical dislocation.
Insulin lispro exposure was determined using a radioimmuno-
assay (RIA) (EMDMillipore, St. Charles, MO, USA) and BIL
exposure was determined using an enzyme-linked immuno-
sorbent assay (ELISA) (Charles River, Senneville, Quebec,
Canada).
LDC and Non-LDC Sheep Model
Using a parallel group design, BIL was administered by single
dose SC injection to non-LDC control sheep and to LDC
sheep with a surgically placed popliteal lymph duct cannula
(Table I). Blood was collected in each group, and lymph was
continuously collected in the LDC sheep. BIL was also admin-
istered by bolus IV injection to a separate group of non-LDC
animals for determining bioavailability and PK linearity.
Surgery was performed under aseptic conditions.
Castrated male merino sheep (H.M. Barty & Sons Merino
Stud, Robinvale, Victoria, Australia) weighing 31–48 kg were
used. All animals had surgical cannulation of one jugular vein
for blood collection via the insertion of a polyethelene cannu-
lae (1.70 × 1.20 mm) (Microtube Extrusions, North Rocks,
Australia), while animals in the LDC group had an additional
3 French heparin-coated polyurethane cannula inserted into
the efferent popliteal lymph duct. Animals were prepared for
surgery as previously described (26), and the efferent popliteal
lymph duct was accessed and cannulated as previously de-
scribed (13,20). Water and food was available ad libitum during
recovery and sampling periods.
The sheep were dosed with a flat dose of insulin peglispro
assuming a 40 kg sheep and then the exact weight based dose
was calculated for each sheep. A single IV bolus dose of
20 nmol (0.5 nmol/kg), 40 nmol, (1.0 nmol/kg), or 120 nmol
(3.0 nmol/kg) insulin peglispro (diluted as required with for-
mulation diluent comprising 16.5 mM TRIS; 29 mM m-cre-
sol; 128 mM NaCl; 0.39 mM zinc oxide (pH 7.3) in sterile
water for injection) was administered into the jugular vein
opposite the cannulated jugular vein used for blood collection.
A single SC dose of 120 nmol (3.0 nmol/kg) insulin peglispro
was injected using a 25 g needle into the interdigital space
below the point of lymph cannulation for LDC sheep and
the interdigital space of either leg for non-LDC sheep.
Samples were taken from 3 to 5 sheep per dose group.
Blood samples (3 mL) were collected into 4 mL serum
collection tubes (Becton, Dickinson and Company, Scoresby,
Victoria, Australia) at the following time points (hour):
predose, 0.0163 (1 min, IV only), 0.083 (5 min, IV only),
0.25 (15 min, IV only), 0.5, 1, 2, 3 (SC LDC only), 4, 6, 8,
10, 12 (all IV and SC LDC), 18 (SC non-LDC only), 30 (all
SC), 39 (SC non-LDC only), 48 (all SC), 54 (all SC), 72 (all
SC), 96 (SC LDC only), and 120 (SC LDC only) hours
postdose. The jugular cannula was flushed with heparinized
saline (50 IU/mL) between samples to maintain patency.
Blood samples were allowed to stand at room temperature
for up to 1 h and were then centrifuged for 10 min
6000 rpm to separate serum. Serum was stored at 4°C for
up to 12 h and at −80°C for long term storage.
In LDC sheep, lymph samples were collected in pre-
weighed tubes containing 10 μL/mL of 10% EDTA at the
following time points: Predose, 0–1, 1–2, 2–3, 3–4, 4–5, 5–6,
6–7, 7–8, 8–9, 9–10, 10–11, 11–12, 12–24, 24–36, 36–48,
48–60, 60–72, 72–84, 84–96 h post dose. At each time inter-
val, the amount of lymph collected was determined gravimet-
rically. Lymph samples were stored at 4°C for up to 12 h and
at −80°C for long-term storage.
Aliquots of lymph and serumwere shipped on dry ice to the
bioanalytical site where they were stored at approximately
−80°C until analyzed.
ELISA Assay for BIL
BIL concentrations in serum and lymph were determined by
ELISA performed by the bioanalytical testing facility Charles
River Laboratories Preclinical Services (Senneville, Quebec,
Canada) as described previously for rat serum (27). The assay
quantitation range for rat serum was 20 pM to 500 pM. Assay
quantitation range for sheep serum was from 20 pM to 500
pM. A 10% dilution of serum was used as a surrogate matrix
for the sheep lymph. The quantitation range for sheep lymph
was also 20 to 500 pM. Samples above the upper limit of







LDC SC 3 120 Serum/Lymph
LDC IV 3 120 Serum/Lymph
non-LDC SC 3 120 Serum
non-LDC IV 3 120 Serum
non-LDC IV 1 40 Serum
non-LDC IV 0.5 20 Serum
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quantitation were diluted and reanalyzed to gain results with-
in the calibrated range. The assays were validated (serum) or
verified (lymph) using quality control samples at three differ-
ent concentrations. The measure of precision (relative stan-
dard deviation) and the measure of accuracy (relative error)
for the serum-assays were ≤15% across the quantitation range.
For the lymph-assay, the relative standard deviation and rel-
ative error were ≤20% across the quantitation range. BIL was
shown to be stable in frozen serum and lymph.
RIA Assay for Insulin Lispro
Insulin lispro in rat serum was determined using an RIA for
insulin lispro at EMD Millipore (St Charles, MO). The assay
quantitation range was 10 pM to 5000 pM. Samples with
concentrations higher than 5000 pMwere diluted before anal-
yses to yield a concentration within the quantitation range.
Pharmacokinetic Data Analyses
Noncompartmental pharmacokinetic parameters for the rat
study were determined using WinNonlin® professional v5.3
(Pharsight, St. Louis, MO, USA) and for the sheep study using
WatsonTM (version 7.4.2 PRD872, Thermo Fisher Scientific,
Inc). Concentrations below the lower limit of quantitation
were assigned a value of zero and the zero result used in the
calculation of means and standard deviation using
MicroSoft® Office® Excel® 2010 (version 14.0.; Redmond,
WA). Descriptive statistics were calculated as appropriate.
SigmaPlot® v11 (Systsat Software, IC., San Jose, CA, USA)
and Excel® were used for the graphics.
RESULTS
Hydrodynamic Size
Using DLS to measure hydrodynamic size, BIL displayed a
hydrodynamic diameter of 7.6 nm (±0.6 nm), whereas insulin
lispro displayed a hydrodynamic diameter considerably small-
er, 2.1 nm (±0.3 nm). Although the MW of BIL is only
26 kDa, the hydrodynamic diameter is similar to human se-
rum albumin, which has a MW of 67 kDa (~7.2 nm) (28). The
hydrodynamic size for insulin (MW= 6 kDa) was 2.1 nm, and
the hydrodynamic size for leptin (MW= 16 kDa) was 4.3 nm.
Pharmacokinetics in 5/6-Nephrectomized Rats
After IV administration to sham rats, the C0 and AUC of
BIL were higher than the C0 and AUC for insulin lispro
(Fig. 1; Table II). The clearance of BIL was slower than
that for insulin lispro in the sham rats and the volume of
distribution was lower. In sham rats, the clearance of BIL
was reduced ~65-fold versus insulin lispro, from 2.24 L/
hr/kg to 0.035 L/hr/kg. In 5/6-nephrectomized rats,
where the contribution of renal clearance should be min-
imal, the clearance of BIL was ~20-fold less than the
clearance of insulin lispro, but was similar to sham rats
administered with BIL. For insulin lispro, the clearance in
the 5/6-nephrectomized rats was reduced 3.3-fold when
compared to sham rats suggesting an impact on clearance
by renal impairment, while the clearance of BIL was sim-
ilar in sham and 5/6-nephrectomized rats.
Pharmacokinetics in Non-LDC Sheep
The pharmacokinetics of BIL in non-LDC sheep were deter-
mined after IV administration of 20 nmol, 40 nmol, and
120 nmol of BIL as well as after SC administration of
Fig. 1 Pharmacokinetic profiles for BIL (a) and insulin lispro (b) in sham and
5/6-nephrectomized rats. BIL was tested in 2 independent studies and insulin
lispro was tested in 3 independent studies. BIL (a): sham groups (n=13,
closed squares); 5/6-nephrectomized groups (n=16, open squares). Insulin
lispro (b): sham groups (n=24, closed squares); 5/6-nephrectomized groups
(n= 28, open squares). All data are represented as mean ± SD.
Abbreviations: BIL basal insulin peglispro.
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120 nmol. After IV administration, exposure increased line-
arly as the dose increased from 20 nmol to 120 nmol
(Table III). The mean half-life of BIL ranged from ~2–3 h
after IV administration in non-LDC sheep and was more than
doubled to ~8 h after SC administration in non-LCD sheep
(Table IV).
Pharmacokinetics of BIL in LDC and Non-LDC Sheep
The mean serum concentrations of BIL after a single SC
dose of 120 nmol BIL showed 50 to 100-fold higher con-
centrations in non-LDC sheep compared to LDC sheep
(Fig. 2). The AUC for 120 nmol SC administration in
LDC sheep was <2% of the AUC in non-LDC sheep,
but after 120 nmol IV administration the AUCs were
similar in LDC and non-LDC sheep. The absolute bio-
availability after SC administration to non-LDC sheep
was 123.0%, but decreased to 1.7% for the LDC sheep
administered the same dose (Table IV).
In LDC sheep, 88% (±19% standard deviation [SD];
61%–102% range) of BIL was recovered in the peripheral
lymph after SC dosing compared to 0.06% (±0.02%; 0.04–
0.08%) recovered after IV dosing. Figure 3 shows the cumu-
lative amount of BIL collected in lymph after a single 120 nmol
IV or SC dose.
DISCUSSION
The addition of a single linear 20-kDa PEG to insulin
lispro resulted in a molecule of insulin lispro with a hy-
drodynamic size of 7.6 nm rendering the molecule a size
similar to or greater than albumin. The results presented
herein demonstrate that the addition of a 20-kDa PEG to
insulin lispro leads to changes in both the absorption and
clearance of insulin lispro. The renal clearance of BIL
compared to insulin lispro decreased in the rat. Renal
impairment did not appear to alter the clearance of BIL
in the 5/6-nephrectomized rat model. The differences in
clearance seen in the 5/6-nephrectomized rats between
BIL and insulin lispro can be attributed to a reduction
in renal clearance of BIL. In total, the rat data suggests
that PEGylation of insulin lispro increases the hydrody-
namic size of insulin lispro beyond that associated with
molecular weight changes, contributing to a decreased
clearance, which contributes to the prolonged duration
of action of BIL.
In a previously reported study in diabetic rats, the clear-
ance of total insulin was decreased 13-fold after BIL adminis-
tration compared to after insulin lispro administration and the
AUCwas increased 10-fold after BIL administration (29). The
Tmax for total insulin after administration of BIL was approx-
imately 24-fold longer than that after insulin lispro adminis-
tration. These data indicated that in rats, both absorption and
clearance were impacted by the PEGylation of insulin lispro to
yield BIL.
The absorption of BIL was predominately lymphatic
absorption, which may have affected the rate of absorp-
tion. The delay in absorption could be due to the re-
quirement for lymphatically transported drugs to pass
through the lymphatics prior to reaching the systemic
circulation and/or related to a slower transport through
the interstitium to reach the lymphatic capillaries. In
general, however, lymphatic transport is rapid, and
Table II Pharmacokinetic
Parameters for IV-injected 10 nmol/
kg Insulin Lispro and BIL in 5/6-
nephrectomized Sprague–Dawley
Rats
Mean (SEM) Insulin Lispro BIL
Model 5/6 Sham 5/6 Sham
C0 (nM) 184 (38) 123 (31) 295 (22) 239 (22)
AUC0-∞ (nM× hour) 15 (1.4) 4 (0.5) 305 (16) 287 (19)
CL (L/hour/kg) 0.67 (0.064) 2.24 (0.262) 0.033 (0.0017) 0.035 (0.0023)
Vdss (L/kg) 0.13 (0.022) 0.42 (0.087) 0.050 (0.004) 0.059 (0.007)
Table III Pharmacokinetic
Parameters in Serum After IV
Administration of BIL to non-LDC
Sheep
Parameter BIL (Mean ± SD)
Number (N) 3 4 3
Dose (nmol) 20 40 120
AUC0-t (pM× hours) 12566.7± 1800.9 40075.0 ± 12458.3 111666.7± 15044.4
T1/2 (hours) 1.6± 0.1 2.8 ± 0.3 3.3± 1.2
CL (mL/min/kg) 0.70± 0.09 0.53± 0.21 0.47± 0.06
Vdss (L/kg) 0.05± 0.01 0.04± 0.01 0.07± 0.04
C0 (pM) 11133± 1234 27900± 6124 60400± 1039
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previous studies exploring intestinal lymphatic transport
of, for example, lipophilic small molecules in dogs (where
absorption is rapid) have shown complete transport
through the lymphatic in approximately 1 to 2 h (30).
It seems likely, therefore, that the effect on absorption
rate here reflects slower transport across the interstitial
space to the lymphatic capillaries rather than slowed
transport through the lymphatics, although the data are
not definitive. Similar Tmax data for BIL absorption into
the blood in non-LDC and LDC sheep suggests that
absorption rates into blood and lymph are similar, pro-
viding support for the suggestion that transport through
the lymph is rapid. Several animal models used in mea-
suring the contribution of the lymphatic system to
parenterally-administered macromolecules have demon-
strated that higher MW molecules are more readily
absorbed through the lymphatic system following SC in-
jection (14,20,31–33), but no data are available on hy-
drodynamic size and lymphatic absorption. The LDC-
sheep model showed that the large hydrodynamic size
of BIL increases the role of the lymphatic system in
absorption of BIL, beyond that associated with molecular
weight changes, after SC administration.
Because one assumption of the bioavailability calculation
in the sheep model is PK linearity, non-LDC sheep were ad-
ministered increasing doses of BIL. The increase in mean
serum concentrations and AUC for each dose indicated that
the PK of BIL in sheep was linear and the LDCmodel is valid.
The increase in half-life observed with SC (~8 h) versus IV
(~3 h) injection in non-LDC sheep indicated absorption rate-
l imited ( ie , f l ip- f lop) pharmacokinet ics af ter SC
administration.
After SC administration, when the lymph was collected,
the AUC (exposure/bioavailability) and mean serum concen-
trations of BIL in LDC sheep were greatly reduced compared
with non-LDC sheep reflecting the fact that the dose was
collected in the lymph and removed before reaching the sys-
temic circulation. However, after IV administration, when
lymph was collected, the AUCs were similar n LDC sheep
and non-LDC sheep, with <1% of the dose recovered in the
lymph of LDC sheep. Access to the peripheral lymphatics via
equilibration across peripheral capillary beds (rather than
Table IV Pharmacokinetic
Parameters in Serum After
Administration of 120-nmol BIL to
Sheep
Parameter (Units) BIL (Mean ± SD)
Number (N) 4 5 4 3
Route SC (LDC) SC (non-LDC) IV (LDC) IV (non-LDC)
AUC0-t
(pM× hours)
2594.5±2563.6 142960.0± 83820.7 139500.0 ± 60693.2 111666.7± 15044.4
T1/2 (hours) 4.6 ± 4.0
a 7.5± 5.1 5.7 ± 2.1 3.3± 1.2
CL (mL/min/kg) NA NA 0.37± 0.12 0.47± 0.06
Vdss (L/kg) NA NA 0.04± 0.01 0.07± 0.04
C0 (pM) NA NA 70175.0 ± 13600.1 60400± 1039.2
Tmax (hours) 2.3 ± 1.0 2.4± 0.9 NA NA
Cmax (pM) 415.3 ± 384.0 18766.0± 7833.3 NA NA


























Fig. 2 Mean (SD) serum
concentrations vs time for LDC and
non-LDC sheep after
administration of 120 nmol BIL
either SC or IV. The mean is for 3 to
5 sheep per group. Abbreviations:
BIL basal insulin peglispro, LDC
lymph duct cannulated, IV
intraveneous, SC subcutaneous, SD
standard deviation.
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direct access at the injection site) was therefore low, suggesting
that BIL is primarily absorbed via the lymphatic system after
SC administration.
The increase in hydrodynamic diameter of BIL due to
the 20-kDa PEG moiety (7.6 nm vs 2.1 nm for insulin
lispro) was similar to the increase observed by addition
of 20-kDa PEG to 14.3-kDa egg white lysozyme (9.6 nm
vs. 4.0 nm) (28,34,35). This marked increase in hydrody-
namic size, relative to the MW of BIL, suggests that the
PEG is a conformationally dynamic random-coil struc-
ture; thus, decoupling size from MW (28,36). This dynam-
ic movement of the PEG and the resulting increase in
hydrodynamic size helps to explain the minimal renal
clearance of 20-kDa mono-PEGylated insulin lispro spe-
cies based on sieving coefficient analysis performed with
molecules having different Stokes-Einstein radii (37).
Similar to the results in the 5/6-nephrectomized rat mod-
el, the PK properties of BIL have been shown to be un-
affected by renal insufficiency in humans (38), whereas
insulin undergoes substantial renal clearance (39–41).
Previous studies in rats showed that after SC administra-
tion only 2.5% of a dose of BIL is excreted unchanged in
urine and 11% after IV administration (27).
The hydrodynamic size of BIL likely accounts for much
of the increase in lymphatic absorption of BIL in the cur-
rent study (88%) versus the amount of recovered insulin
observed in a previous study (17%) (13). The correlation
observed between hydrodynamic size of BIL with percent
dose recovered in peripheral lymph shows that increasing
hydrodynamic size of insulin lispro with the addition of
20-kDa PEG can readily shift absorption of insulin to
lymphatic capillaries versus blood capillaries by altering
paracellular transport in the microvascular beds
(14,17,18,20,31–33). Previous studies have correlated the
percent of lymphatic absorption with the MW of admin-
istered proteins (14,20,31–33). However, the results from
this study suggest that for exogenously administered insu-
lin a better indicator of lymphatic absorption may be hy-
drodynamic size. The percent of lymphatic absorption in
the LDC-sheep model of insulin, leptin and BIL are plot-
ted versus the hydrodynamic size in Fig. 4.
CONCLUSION
These results suggest that the increased hydrodynamic size of
insulin lispro with the addition of 20-kDa PEG in BIL likely
alters paracellular transport leading to a slowing of the rate of
absorption of BIL into the serum/plasma compartment and
that this occurs simultaneous with a shift in the absorption
process from absorption into the blood capillaries to absorp-
tion via the lymph capillaries. It seems likely, however, that the
slower rate of absorption of BIL when compared with insulin
lispro reflects slower diffusion or convection across the inter-
stitial injection site to either blood or lymph capillaries, rather
than intrinsically slow lymphatic transport. At the same time,
the addition of 20-kDa PEG significantly reduces renal clear-
ance compared with that of insulin lispro, resulting in en-


































Fig. 3 Mean (SD) percent of dose
recovered in lymph from LDC and
non-LDC sheep after administra-
tion of 120 nmol of BIL either SC or
IV. The mean is for 3 to 5 sheep per
group. Abbreviations: BIL basal in-
sulin lispro, IV intravenous, LDC
lymph duct cannulated, SC subcu-

















Fig. 4 The percent recovery of BIL in peripheral lymph is greater than that of
both insulin and leptin which have smaller hydrodynamic sizes. The line rep-
resents the linear correlation. BIL basal insulin peglispro, DH = 7.6 nm
(±0.6 nm), Insulin DH= 2.1 nm, Leptin DH= 4.2 nm.
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means to increase the systemic exposure of insulin after SC
administration by changes in both absorption and clearance.
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